Psoriasis is a chronic, systematic, inflammatory disease in which multiple metabolic and immunologic disturbances lead to lipid abnormalities, impaired glucose tolerance, metabolic syndrome, diabetes mellitus, atherosclerosis, hypertension, ischemic heart disease, and numerous metabolic disorders. In clinical practice, the most commonly used drugs in the treatment of lipid abnormalities are statins and fibrates. Statins are characterized by pleiotropic effects such as antioxidant, anti-inflammatory, anticoagulant, and antiproliferative. They work by reducing the concentrations of low-density lipoprotein (LDL), total cholesterol, and triglycerides and stabilizing atherosclerotic plaque. Fibrates are medications, which help to lower triglycerides, LDL, very low-density lipoprotein (VLDL) levels and increase lower high-density lipoprotein (HDL). In recent years, many new drugs were found to normalize the lipid profile in patients with psoriasis: glitazones (pioglitazone, troglitazone), and glucagon-like peptide-1 (GLP-1) receptor agonists. Pioglitazone improves the lipid profile, including the decrease of triglycerides, fatty acids, and LDL, as well as the increase of HDL. Glucagon-like peptide 1 (GLP-1) analogs decrease modestly low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides. The purpose of this study is to assess the current state of knowledge on the effect of different hypolipidemic treatments on the course of psoriasis. The study includes literature from medical databases PubMed and Google Scholar. We were browsing PubMed and Google Scholar until the beginning of December. The systematic review includes 41 eligible original articles.

Acne vulgaris is a common chronic inflammatory disorder of the pilosebaceous unit that is increasingly recognized as a condition linked to systemic metabolic disturbances. Growing evidence suggests that alterations in lipid metabolism, both in sebum composition and circulating lipid profiles, may play a key role in acne pathogenesis. This narrative review aims to summarize current knowledge on the relationships between lipid metabolism, body composition, diet, and acne. Acne vulgaris should be considered not only a dermatological condition but also a disorder with metabolic components. A deeper understanding of lipid-related mechanisms may support the development of more personalized and metabolically targeted therapeutic strategies.

Introduction: Grover's disease (transient acantholytic dermatosis) is a rare skin disease characterised by papules or vesicles located mainly on the chest and proximal limbs, and accompanied by pruritus. The disorder is most prevalent in elderly men. Histopathologically, it presents with foci of acantholysis and dyskeratosis. The course of the disease is usually mild, however systemic therapy might be required. Objective: To present the case of a patient with Grover's disease. Case report: A 78-year-old man after resection and radiotherapy for prostate cancer was admitted to the Dermatology Department for the diagnosis of multiple papular and vesicular eruptions located on the torso and limbs. The skin lesions were accompanied by pruritus which intensified after sweating and hot baths. Based on the results of histopathological and clinical examinations, the diagnosis of Grover's disease was made. Oral acitretin at 25 mg/day was initiated. The skin condition improved significantly, and pruritus resolved. Conclusions: On account of the rarity of the condition and polymorphic skin lesions, the diagnosis and treatment of Grover's disease can be a challenge.